Poland · Advertising framework
Outdoor and place-based advertising for prescription medicines in Poland
General market orientation, not campaign clearance. Research scope and dates
Key restrictions and conditions
Public advertising of prescription medicines is prohibited
Legal requirement — paraphrased
Do not plan a public prescription-medicine promotion in this channel. A consented mailing or a social-media age gate does not turn recipients into authorised healthcare professionals.
The statutory vaccination exception needs a separate assessment against the GIS vaccination communication. Professional promotion requires a genuinely restricted route and its own information requirements.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612 · Article 57; advertising regulation section 12
First decide whether the message is medicine advertising
Legal requirement — paraphrased
Promotion intended to increase prescribing, supply, sale or consumption falls within the medicine-advertising regime. Unbranded disease education is excluded only if it makes no even indirect reference to medicines. Advertising must be conducted by, or commissioned by, the marketing-authorisation holder.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612 · Articles 52 and 60
Product and service rules
Use authorised, balanced medicine information
Legal requirement — paraphrased
Do not advertise unauthorised medicines or claims inconsistent with the SmPC. Public advertising cannot target children or use celebrity, scientist or medical/pharmacy-professional presentation or recommendations. No guaranteed cure, absence-of-side-effects or natural-means-safe claims; no purchasing rewards.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; GIF — Advertising medicinal products · Articles 53, 55–57
Professional promotion is a separate restricted route
Legal requirement — paraphrased
Applies when: The recipients are eligible professionals and distribution is genuinely restricted.
If this channel is genuinely restricted to eligible professionals, use the professional-advertising regime, including SmPC-based information, prescribing category, relevant reimbursement information and dated supporting documentation. Do not make the material publicly accessible merely by labelling it professional.
Since 22 July 2026, section 12(4a) allows the specified professional information to be supplied electronically or through a QR/Data Matrix code or web address pointing to the responsible advertiser's site/platform. This is not an exemption for public consumer advertisements.
Sources: Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648; Medicine advertising amendment — Dz.U. 2026 item 910 · Section 12, including new paragraph 4a
Channel rules
Make the overall message truthful and commercially identifiable
Legal requirement — paraphrased
Misleading claims, material omissions, hidden commercial intent and aggressive consumer marketing are prohibited. Assess visuals, comparisons, qualifications and the impression on vulnerable consumers. Do not falsely claim that a product cures illness.
Editorial control: retain substantiation before publication, remove fabricated urgency or authority badges, and check that qualifications do not contradict the headline. Paying to publish apparently independent advice must not conceal its commercial nature.
Sources: Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Articles 4–9; Article 7 hidden advertising and false cure claims
Check price reductions only after establishing that promotion is lawful
Legal requirement — paraphrased
Where an advertisement announces a reduction for a good or service, state the relevant lowest price from the preceding 30 days alongside the reduced price. For a shorter selling history, use the lowest price since sales began; special rules apply to rapidly perishable goods.
This consumer-information rule does not permit a discount or purchasing incentive prohibited by medicine or service rules. As an editorial check, make the total scope and extra charges clear.
Sources: UOKiK — Information about price reductions · Price Information Act Article 4 as explained by UOKiK
Keep reviews genuine and explain verification
Legal requirement — paraphrased
Do not publish, commission or distort false consumer recommendations. If making consumer reviews available, explain whether and how their origin is verified. Do not claim authentic-user verification without reasonable, proportionate checks.
Selecting a patient or customer story for advertising also requires checking the sector's claims and endorsement restrictions. A genuine testimonial can still contain an unlawful health claim.
Sources: UOKiK — False reviews? Stop!; Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Unfair-practices Act Articles 6–7; UOKiK reviews guidance
Check the display format and the place of display
Editorial recommendation
Static posters need the applicable visual advertising assessment; digital screens with sound/video need the corresponding format assessment. Recommended legibility check: review viewing distance, screen rotation and exposure time; a code leading to a website does not repair mandatory content missing from the display.
Public device advertising inside pharmacies/retail sites must use designated fixed areas without obstructing customer space; in healthcare premises it is confined to waiting rooms. Audio and audiovisual device advertising are prohibited in the premises specified by section 5. These location rules concern device advertisements, not every clinic sign.
Sources: Medical-device advertising regulation — Dz.U. 2023 item 817; Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648 · Device advertising regulation section 5; visual/audiovisual sector rules
Campaign workflow
Keep one campaign evidence and approval record
Editorial recommendation
Recommended workflow: record the exact offer and legal classification, advertiser, selected channel and creative formats; list permitted claims and evidence; review the Polish execution and destination; record sign-off, publication and corrections.
Keep the source date with the rule. Recheck legislation flagged as changing, especially pharmacy advertising. Preserve statutory archive periods where they apply; this suggested general workflow does not create a universal retention period.
Sources: URPL — Advertising medical devices; Sejm official API — Pharmacy advertising amendment, process 3002 · Specific retention and legislative-watch sources; workflow is editorial
Pre-publication checklist
- Stop public Rx promotion; document any claimed statutory exception before developing creative.
- Verify recipient eligibility and access restrictions before treating a placement as professional promotion.
- Record the category gate before reviewing the channel.
- Approve the final creative, disclosure, targeting and landing page together.
- Assign an owner for corrections, expiry of claims and legislative updates.
Scope and unresolved questions
- Product authorisations, intended users, approved documentation and final Polish creative must be checked for the actual offer. Veterinary products, controlled substances, vaccine exceptions and specialist product subtypes are not separately cleared by this category-level guide.
- Check local landscape/signage rules, site permissions and any road/public-space requirements for the actual address; no municipality-specific permission is established here.
Research scope, introduction and dates
For prescription medicines on outdoor and place-based displays in Poland, the first question is whether the message reaches the public or a genuinely restricted professional audience. Start with the advertising prohibition and any applicable exception before considering the creative.
A poster, digital screen and waiting-room display raise different execution questions. Assess viewing distance, display format and location together, preserving the specific restrictions that can apply inside healthcare or retail premises.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
Resolve product and service restrictions before choosing a channel
Editorial overview
A platform label, newsletter consent, an advertising warning or a publisher's acceptance does not create permission to advertise. Apply the selected product/service gate first; if public promotion is prohibited, use this guide to identify the restriction and alternatives for specialist review.
This English guide describes Polish requirements. Required Polish warning text and locally understandable disclosure remain necessary where the law requires them.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156; Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620 · Product/service rules referenced in matching modules
Sources
- Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612
Consolidation reflects 8 April 2026. Later amendments exist; pharmacy advertising must also be read with the CJEU judgment and the October 2026 legislative tracker in the pharmacy framework. This is a targeted advertising review, not an audit of the entire Act.
- Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156
Public information must not have advertising characteristics. Information supplied at a patient's request under paragraph 2 is a different context.
- Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620
The inspected PDF is dated 19 November 2024. Advertising provisions were cross-checked against the current URPL advertising overview; recheck amendments before campaign sign-off.
- GIF — Advertising medicinal products
The warning quoted on this older overview is superseded; use the medicine advertising regulation for warnings.
- Medicine advertising regulation — consolidated text, Dz.U. 2023 item 1648
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- Medicine advertising amendment — Dz.U. 2026 item 910
Adds electronic/QR delivery of required information in professional advertising. Does not remove public-advertising warnings or relax the public Rx ban.
- Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845
- UOKiK — Information about price reductions
- UOKiK — False reviews? Stop!
The 30 July 2024 announcement also describes enforcement decisions; their subsequent appeal status is not asserted here.
- Medical-device advertising regulation — Dz.U. 2023 item 817
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- URPL — Advertising medical devices
- Sejm official API — Pharmacy advertising amendment, process 3002
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
From framework to action
Local expertise in Poland
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Poland.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
Marketing & sales advisory
Casbeg
Marketing and sales consulting for businesses in Poland: strategy, commercial processes, lead generation and CRM implementation.
View partner profileBusiness & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.